-
Nov 16, 2024
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
>The UK MHRA has approved toripalimab for the treatment of NPC and ESCC
View details -
Oct 12, 2024
Junshi Biosciences Announces Ongericimab’s NDA Approval in China
>The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)
View details -
Sep 25, 2024
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
>The European Commission has approved toripalimab for the 1st-line treatment of advanced NPC and ESCC
View details -
Apr 7, 2024
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
>The NMPA has approved the supplemental new drug application for toripalimab in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma
View details